TrialAmerican journal of clinical dermatology2025

Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study.

Andrew Alexis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.